Nivolumab and ipilimumab drug combination has been approved for first-line treatment of unresectable malignant pleural mesothelioma in adults.
The German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether it offers an added benefit to the patients.
The effect depends on a subgroup characteristic, i.e. "tumour histology": For patients with non-epithelioid mesothelioma, there is an indication of considerable added benefit compared to platinum-based chemotherapy ...
Nivolumab and ipilimumab drug combination has been approved for first-line treatment of unresectable malignant pleural mesothelioma in adults.
The German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether it offers an added benefit to the patients.
The effect depends on a subgroup characteristic, i.e. "tumour histology": For patients with non-epithelioid mesothelioma, there is an indication of considerable added benefit compared to platinum-based chemotherapy ...